Human PCSK9 (D374Y), His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 72.0 kDa. The predicted N-terminus is Gln 31. The reducing (R) protein migrates as 17 kDa and 66 kDa in SDS-PAGE due to glycosylation and proteolytic digestion. The D374Y mutation results in higher affinity of PCSK9 for LDLR.
>92% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
Human PCSK9 (D374Y), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 92%.
FACS analysis shows that Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 0.0689-0.3049 μg/mL.
FACS analysis shows that the effect of Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibiting LDL uptake in HepG2 cells was neutralized by anti-human PCSK9 antibody. The concentration of PCSK9 used is 5 μg/ml. The EC50 for anti-human PCSK9 antibody is 6.816-12.67 μg/mL.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $260.00
Price(USD) : $1980.00
This web search service is supported by Google Inc.